These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8819928)

  • 1. [The characteristics of the immunological indices in multiple myeloma during polychemotherapy].
    Abdulkadyrov KM; Bessmel'tsev SS
    Lik Sprava; 1995; (3-4):75-80. PubMed ID: 8819928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological and rheological disorders in multiple myeloma patients].
    Abdulkadyrov KM; Bessmel'tsev SS; Liubimova NIu
    Ter Arkh; 1991; 63(7):122-6. PubMed ID: 1788790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of immunological and cytochemical studies of the peripheral blood lymphocytes in myeloma patients during polychemotherapy].
    Golenkov AK; Andreeva OK; Zlatkina AR; Cheredeev AN
    Gematol Transfuziol; 1984 Feb; 29(2):19-22. PubMed ID: 6608470
    [No Abstract]   [Full Text] [Related]  

  • 4. [Status of the immune system in multiple myeloma during polychemotherapy].
    Golenkov AK; Cheredeev AN; Zlatkina AR; Konstantinpva NA; Mattes KH
    Gematol Transfuziol; 1987 Jun; 32(6):9-13. PubMed ID: 3623063
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
    Hansz J; Włodarczyk M; Psuja P
    Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
    van de Donk NW; de Weerdt O; Veth G; Eurelings M; van Stralen E; Frankel SR; Hagenbeek A; Bloem AC; Lokhorst HM
    Leukemia; 2004 Jun; 18(6):1078-84. PubMed ID: 15085157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.
    Mackay IR; Goodyear MD; Riglar C; Penschow J; Whittingham S; Russell IS; Kitchen PR; Collins JP
    Cancer; 1984 Jun; 53(12):2619-27. PubMed ID: 6609758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of immunological indices for assessing the severity of the course of periodontitis and treatment efficacy].
    Bazhanov NN; Ter-Asaturov GP; Kassin VIu; Ivaniushko TP; Arion VIa; Simonova AV
    Stomatologiia (Mosk); 1996; 75(1):15-8. PubMed ID: 8658566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of levamisole on cellular immunity indices in chronic bronchitis and chronic pneumonia patients].
    Borisova AM; Novikova TA; Glazko AV
    Ter Arkh; 1984; 56(10):29-31. PubMed ID: 6335306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of systemic chemotherapy on clinical status and biological and immunologic markers in patients with breast cancer].
    Orlova RV; Chernetsova LF; Matveeva ON
    Vopr Onkol; 2007; 53(4):414-8. PubMed ID: 17969403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of chemotherapy on the killer activity of the peripheral blood leukocytes in patients with multiple myeloma].
    Vozniuk VP
    Lik Sprava; 1998; (2):88-91. PubMed ID: 9670667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [VAD chemotherapy of multiple myeloma].
    Amano M; Itoh K; Togawa A
    Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic lysozyme administration as a tool for immunopotentiation in patients with multiple myeloma.
    Vacca A; Campobasso N; Iodice G; Ronco M; Dammacco F
    Chemioterapia; 1985 Apr; 4(2):147-55. PubMed ID: 3924421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects of PAD and VAD regimens in multiple myeloma patients].
    Zhao Y; Jing Y; Bo J; Li HH; Wang SH; Huang WR; Zhu HY; Han XP; Dou LP; Wang FF; Li F; Gao CJ; Wang QS; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1027-30. PubMed ID: 20723322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
    Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
    Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation.
    Lindemann M; Schuett P; Moritz T; Ottinger HD; Opalka B; Seeber S; Nowrousian MR; Grosse-Wilde H
    Leukemia; 2005 Mar; 19(3):490-2. PubMed ID: 15674357
    [No Abstract]   [Full Text] [Related]  

  • 19. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
    Svane IM; Nikolajsen K; Johnsen HE
    Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.